GlassScriptPhysician profile
Filippo Milano
NPI 1083842215
$60,632.91
in general payments reported to CMS, 2019-2025
10 companies · $24K in 2025
The $24K reported for 2025 was more than what 94% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $5,940 · 2021: $17.25 · 2022: $4,144 · 2023: $245 · 2024: $12K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $36K · Food and Beverage: $729 · Travel and Lodging: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $35,880.00 |
| Food and Beverage | $729.08 |
| Travel and Lodging | $137.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gamida Cell INC. | $21,886.49 | 2023-2025 | Omisirge |
| Medexus Pharma, INC. | $17,735.35 | 2022-2025 | Grafapex |
| Chugai Pharmaceutical Co., LTD. | $13,785.31 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $5,940.00 | 2020 | |
| National Marrow Donor Program | $498.40 | 2022 | |
| Jazz Pharmaceuticals INC. | $473.57 | 2021-2024 | |
| Seagen INC. | $141.26 | 2022 | |
| Legend Biotech USA INC. | $106.24 | 2023-2024 | Carvykti |
| Siemens Medical Solutions USA, INC. | $66.29 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Filippo Milano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.